H.C. Wainwright analyst Mitchell Kapoor downgraded Korro Bio (KRRO) to Neutral from Buy without a price target The firm says that KRRO-110 “falling far short of therapeutic levels,” Korro must now rebuild investor confidence “from the ground up.” Korro’s first look at KRRO-110 “was deeply disappointing,” the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio downgraded to Sector Perform from Outperform at RBC Capital
- Korro Bio downgraded to Market Perform from Outperform at William Blair
- Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Korro Bio downgraded to Market Perform from Strong Buy at Raymond James
- Korro Bio downgraded to Neutral from Buy at Chardan